Surjeet is sick and he visited a doctor… “It is important to finish the whole course of antibiotics. Otherwise, not all bacteria exposed to antibiotics are killed.” “So what? I always feel better after 2-days of medicine.” “These remaining bacteria can become superbugs. If that happens, we cannot kill them using antibiotics anymore.” “OH, I see! I have to then follow your instructions.” We're delighted to share a selection of comics drawn by schoolchildren in India, showcasing their impressive understanding of antimicrobial resistance (AMR) and how it can be prevented. These creative and informative comics were produced during workshops in schools in Rupnagar, Punjab, and Dhunela, Gurgaon. The project was part of the Superheroes Against Superbugs initiative supported by Centrient, with workshops assisted by World Comics India. We think it’s important to empower young people and educate the next generation about the importance of responsible antibiotic use – especially in India, which faces one of the largest burdens of drug-resistant infections in the world. Take a look at the comics – and the students in action! #AMR #AMRawareness #AMReducation #ScienceEducation
Centrient Pharmaceuticals
制药业
Rotterdam,South Holland 71,437 位关注者
Global B2B leader in sustainable, enzymatic antibiotics, next-generation statins and anti-fungals
关于我们
Centrient Pharmaceuticals is the global business-to-business leader in sustainable, enzymatic antibiotics, next generation statins and anti-fungals. We produce and sell intermediates and active pharmaceutical ingredients (APIs), as well as our own tablets, capsules and other finished dosage forms (FDFs). We stand proudly at the centre of modern healthcare, as a maker of essential and life-saving medicines. With our commitment to Quality, Reliability and Sustainability at the heart of everything we do, our over 1,800 employees work continuously to meet our customers’ needs. We work towards a sustainable future by actively participating in the fight against antimicrobial resistance. Founded 150 years ago as the ‘Nederlandsche Gist- en Spiritusfabriek’, our company was known as Gist Brocades and more recently DSM Sinochem Pharmaceuticals. Headquartered in Rotterdam (Netherlands), we have production facilities and sales offices in China, India, the Netherlands, Spain, the United States and Mexico. Centrient Pharmaceuticals is owned by Bain Capital Private Equity, a leading global private investment firm.
- 网站
-
http://www.centrient.com
Centrient Pharmaceuticals的外部链接
- 所属行业
- 制药业
- 规模
- 1,001-5,000 人
- 总部
- Rotterdam,South Holland
- 类型
- 私人持股
- 创立
- 1869
地点
Centrient Pharmaceuticals员工
动态
-
When you think about the deadly threat of antimicrobial resistance (AMR), the first thing that comes to mind might be the overuse and misuse of antibiotics. But for pharmaceutical companies that manufacture antibiotics, as we do at Centrient, there is another critical aspect that must also be prioritized: how can these life-saving medicines be manufactured without contributing to the spread of AMR? Specifically, how can we safely dispose of wastewater and solid waste and monitor air quality from the manufacturing process – which contains antibiotic material – without giving bacteria in the environment any opportunities to develop resistance? Centrient is at the forefront of industry efforts to ensure antibiotic manufacturing does not have the unintended side effect of driving drug resistance. In fact, we are a founding member of the AMR Industry Alliance, a coalition dedicated to curbing AMR. At Centrient, we have a clear purpose: to improve lives through innovative and sustainable manufacturing of medicines. That’s why we’re determined to ensure wastewater discharge from our sites and our suppliers’ sites is safe and does not fuel AMR. By acting now on responsible manufacturing, we can help curb the rise of this global health threat. Check out what we have done so far below!
-
Diseases are an ever-changing, often life-threatening enemy – and when bacteria and fungi adapt their defenses so that antibiotics and antifungals can no longer destroy them, infections become difficult or even impossible to treat. This is called antimicrobial resistance (AMR), and it is one of the top global health threats facing humanity today. Antibiotics are one of the cornerstones of modern medicine, but their effectiveness is being undermined by rising AMR. That puts medical progress at risk, because we need antibiotics to treat everything from urinary tract infections, to septicaemia, to meningitis. Antibiotics are also used during other medical procedures and treatments to decrease risk for patients, such as during surgery, childbirth and chemotherapy for cancer. Unfortunately, the emergence and spread of AMR is accelerating. According to the World Health Organization, the main drivers are the misuse and overuse of antimicrobials in humans, animals and plants. When we unnecessarily expose bacteria to the antibiotics in our arsenal, we give them more and more opportunities to mutate or acquire resistant genetic material, leading to the development of drug-resistant pathogens. AMR is a complex issue to tackle. But it is also absolutely critical. As a key manufacturer of antibiotics, antifungals and other foundational medicines, Centrient is committed to being part of the solution. We’ll be sharing a series of content to raise awareness of AMR and explore how we can combat its spread together – watch this space!
-
-
Watch this insightful video by the World Economic Forum to learn more about AMR as a growing global health threat and how we can work together to combat it. At Centrient, we're leading the charge against AMR, including commitments to treat our wastewater, achieve compliance with PNEC, and maintain our industry leadership by working with key partners to continue addressing this pressing topic.
The UK Special Envoy on Antimicrobial Resistance explains how to tackle this growing crisis. Learn more about antimicrobial resistance in this episode of Radio Davos: https://ow.ly/YVbJ50SSg4L #AMR #antibiotics
-
Eliminating obstacles to antibiotic access is essential for ensuring sustainable availability of key medicines for all. To learn more, explore the AMR Industry Alliance’s Call-to-Action event, which emphasizes the need for responsible antibiotic use and equitable access.
Antimicrobial supply chains must operate smoothly. But in many parts of the world, the supply chain is unstable, leading to limited—and therefore inequitable—antimicrobial access for patients who need them. Removing barriers to registration, accelerating approvals, improving forecasting through better data collection and surveillance, and reforming antimicrobial procurement practices are critical steps the United Nations Member States can take to ensure antimicrobials are accessible to all who need them. Subasree Srinivasan, Gareth Morgan, Ramanan Laxminarayan, and Erika Satterwhite discussed the need to remove barriers to access while also ensuring responsible use at our Call to Action event.
-
Centrient launched a Mobile Healthcare Unit (MHU) in India in 2023 to bridge the gap in healthcare accessibility and deliver quality medical care to populations facing barriers to accessing traditional healthcare facilities. At Centrient, Corporate Social Responsibility (CSR) is a fundamental priority embedded within our ESG strategy. We are thrilled to see our partnership with Spherule Foundation continue to grow and thrive and are proud of the impact the MHU has had, aligning with our purpose of improving lives in the communities where we operate.
A health camp was set up through the 'Mobile Health Unit' project in the village of Taunsa Nim Chowk, SBS Nagar, Punjab. A large number of beneficiaries received essential medical care, including free check-ups and necessary medications, that was provided free of cost. This impactful initiative was made possible thanks to the continuous support of our CSR partner Centrient Pharmaceuticals and the dedicated medical team appointed for this project. Through such contributions, Spherule Foundation committed to reaching and meeting the health needs of these communities and making a significant difference in the lives of many people. Thank you to everyone involved for your efforts in making this mission a reality. #HumanitarianAid #HealthCamp #CommunitySupport #SpheruleFoundation #CentrientPharmaceuticals #HealthcareForAll
-
-
-
-
-
1
-
-
The International Federation of Pharmaceutical Manufacturers and Associations, IFPMA, recently published a report outlining the challenges and opportunities regarding access to safe and quality-assured antibiotics. At Centrient, we are proud to see more awareness surrounding AMR and the steps key stakeholders need to take in order to combat this growing threat. To learn more about the IFPMA's recommendations, read more in their report here: https://lnkd.in/emkpjSaJ.
Antimicrobial Resistance (#AMR) is a pressing global health threat that needs ambitious and impactful commitments. Ahead of the United Nations High-Level Meeting on AMR in September, we call for a set of policy changes that tackle challenges related to access to safe and quality-assured antibiotics – both existing and new. The pharmaceutical industry is committed to playing its part in increasing access to #antibiotics by working with relevant partners and stakeholders to make changes to ensure that patients, everywhere, can access the essential antibiotics they need. Read the report for more details: https://ifpma.info/3S3T2e6
-
Here at Centrient, we're committed to being a sustainable leader in the generics pharmaceuticals space. That's because thinking and acting sustainably is a key pillar of our purpose to improve lives through innovative and sustainable manufacturing of medicines. We channel this approach through our ESG Ambition 2021-2030. Our recently published Environmental, Social and Governance (ESG) Report provides an update on the steps we're taking to realise this ambition and support the health and wellbeing of people and the environment. The report is packed full of information, but here are some of the key highlights from our ESG activities over the past two years: • Environmental: 5% reduction in GHG emissions and new targets submitted to SBTi • Environmental: 97% of waste repurposed and 10% reduction in water consumption • Social: facilitated 1.5 billion patient treatments globally in 2023 • Social: progress on DEI, including 30% of senior management roles held by women • Governance: maintaining our EcoVadis Gold rating • Governance: completing a company-wide human rights impact assessment All this and more in the report here: https://lnkd.in/gvXGRYFg
-
-
As part of our ESG Ambition 2021-2030, we are committed to establishing a high level of employee engagement, aiming to be a leader in the top 10% of our industry by 2025. Conducting an employee engagement survey every two years is integral to this vision, as it helps us create an inclusive environment for our employees. We take immense pride in the progress we’ve made in diversity, equity, and inclusion over the past two years, the outcomes of which are reflected positively in our 2024 employee survey. Below, you’ll find some highlights from the survey, showcasing how our employees feel about working at Centrient. “Only when we harness all the unique talent in our organisation, can we truly unlock the full potential of our business.” – Centrient’s CHRO, Jean-Luc Giraud.
-
-
Our Global Communications & ESG Director, Neil Moorhouse, recently sat down with our Chief Human Resources Officer, Jean-Luc Giraud, to discuss more about Centrient's employee value proposition (EVP) and why Centrient is considered a great place to work. Our EVP is dynamic and continuously evolving to better serve our employees. Offering a wide range of tailored benefits, we ensure that our people feel well cared for. Curious to learn more about what we offer? Check out our interview with our CHRO below! For additional information on our EVP and how we cultivate talent, you can read more in our recently released ESG report here: https://lnkd.in/gvXGRYFg